The records of all patients undergoing open prostatectomy at Hamumersmith Hospital between 1953 and 1967 were examined. During this period there were 629 operations for benign hyperplasia and, on review, 31 had unequivocal cancer, an incidence of 4-9 %. The age of the 31 patients ranged from 59 to 87 years (mean years) (Fig 1) . The majority of patients presented with symptoms of prostatism but, in addition, 6 had hmmaturia and 12 acute retention. All had normal skeletal radiographs and normal serum acid phosphatase. Of the 31 patients, 27 had a transvesical and 4 a retropubic prostatectomy. Difficulty with enucleation was noted in 19 patients. After prostatectomy 29 patients received stilbeestrol; 2 received no treatment.
In this study, all living patients were examined both clinically and radiographically and a serum acid phosphatase value was obtained. All of the dead patients had been seen within six months of death.
Pathology
All of the tumours were adenocarcinomas with a predominantly small acinar architecture (Fig 2) . Neural or perineural involvement was noted in 17 cases. The majority of tumours were well or fairly well differentiated but there was considerable variation from patient to patient as well as in different blocks from the same patient. There were important differences in the size of the tumour; many were truly microscopic, infiltrating only a few medium power fields ( x 10 objective). It was for this reason that an arbitrary division of these patients into two groups was made:
Lf) Group A: Those in whom the tumour occupied less than 12% of the sectioned area of the tissue studied microscopically. There were 11 cases in this group and in 9 the carcinoma infiltrated only 4 % or less of the total sectioned area.
Group B: Those in whom the tumour occupied 40 % or more of the total sectioned area studied. There were 20 cases in this group. We readily admit that the amount of tissue infiltrated by tumour will depend on naked eye selection of blocks for study. In addition, intermediate groups between A and B would no doubt be found in a larger study or in a prospective study. Nevertheless the division adopted here has a practical value which will be discussed.
Results
Sixteen patients are alive and none has evidence of metastases. Their survival ranges from 17 to 152 months (mean 56-7 months); 12 have survived at least 3 years and 6 have survived at least 5 years.
Fifteen of the 31 patients have died. Of these, 3 died within 3 months of operation but the remainder survived 15-88 months (mean 30A4 months). One of the early deaths, in the postoperative period, was found to have residual local tumour and nodal metastases at necropsy. The cause of death was known in 7 but the remainder died from unspecified causes.
Of the Group A patients, 7 are alive, while the cause of death is known in 3 of the 4 dead patients. None is known to have died of the disease or to have had a recurrence.
The results for Group B patients showed 9
were alive, 6 had died from causes other than prostatic cancer, 2 died from tumour with metastases, one post-operative death showed residual local tumour, and in 2 the cause of death was unknown.
The survival curve for the 31 patients in this study was compared with the curve for subjects of similar ages in the United Kingdom (Fig 3) .
This showed that the survival rate for patients with Stage 1 carcinoma of the prostate compared well with that for the general population.
Discussion
The occurrence of incidentally diagnosed carcinoma of the prostate, 4.9 %, was less than the 9-16% reported by others (Smith & Woodruff 1950 , Grabstald 1965 . However, the observation that 3 of the 31 patients died of their disease is similar to the report by Montgomery et al. (1961) .
There are four alternatives in the management of these patients -no treatment, oestrogens, radical prostatectomy, or radiotherapy. In the present study all but 2 patients received cestrogens so that no conclusion can be drawn on the effect of treatment without cestrogens. It is relevant to note the high incidence of cardiovascular complications in cestrogen-treated early prostatic cancer reported by the recent multi-centre study in (Lehman et al. 1968) . None of our patients would have fulfilled this criterion. Culp (1968) , while reporting good results from radical prostatectomy, has suggested that patients over 70 should be treated conservatively because of the high rate of cardiovascular complications.
In addition, radical prostatectomy has a considerable mortality and morbidity (Campbell et al. 1963) which are further increased when radical prostatectomy follows enucleation (Goodwin 1952) .
The value of radiotherapy in the treatment of carcinoma of prostate, while encouraging (Budhraja & Anderson 1964) , has yet to be demonstrated in a controlled trial.
The prognosis, as might be expected, appeared to be related to the size of the tumour. Group A patients had a very good prognosis and none in the present study died of prostatic carcinoma. The prognosis in Group B, though not as good as in Group A, was better than might have been anticipated. Assuming that some of those who died were developing metastases, approximately 20% of this group may have had prostatic metastases. This figure still indicated a better prognosis from Group B compared with those who had overt prostatic carcinoma.
We have concluded that, for the very small focus of prostatic cancer, oestrogen therapy causes no harm, but it is very likely that no treatment is necessary. The prognosis for the larger focus is also good and it would seem unnecessary to consider radical surgery for this group; the precise value of cestrogen therapy in this group will be determined only by an 
